Intellia Therapeutics is trading 5.04% higher at $11.99 on September 29, 2026, with the reason for the session’s gain unclear. - The FDA accepted the lonvo-z application for priority review on September 8, important prior context that does not establish the cause of this move. - Major indices are nearly flat or slightly lower, and available evidence does not point to a broader-market explanation.